Regulatory & Safety

(Image: Getty/BobHemphill)

Takeda sheds products in emerging markets in $200m deal

By Ben Hargreaves

Takeda has sold selected prescription and OTC products to Acino covering its Near East, Middle East and Africa portfolio, as it looks to trim down its portfolio following the acquisition of Shire.

(Image: Getty/Nadzeya K)

Nine ingredients to promote biosimilar uptake

By Ben Hargreaves

Though the utilization of biosimilars in Europe is high, a report on the practices of eight countries suggests that more can be done to foster competition and remove barriers to entry.

(Image: Getty/Klebercordeiro)

Lilly expands migraine offerings after FDA approval

By Ben Hargreaves

US FDA gives marketing authorization to Lilly’s oral medication for the acute treatment of migraines in adult patients, adding to its Emgality approval almost exactly a year ago.

(Image: Getty/Robert Daly)

UCB set to buy Ra Pharma for $2.1bn

By Ben Hargreaves

With both boards of directors in agreement, UCB is on track to add the clinical stage biopharma company and its lead drug candidate, zilucoplan, to its portfolio.

(Image: Getty/Kevron2001)

FDA aims to speed naloxone generics to market

By Ben Hargreaves

US FDA follows up the first generic approval of naloxone nasal spray by encouraging companies to apply with generic applications amid the North American opioid crisis.

(Image: Getty/NicoElNino)

Ranitidine recalls sweep globe

By Ben Hargreaves

US, Canadian, South Korean, and Indian authorities recommend the recall of certain ranitidine medicines due to cancer-causing impurity.